Elementis (ELM) H2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2025 earnings summary
5 Mar, 2026Executive summary
Achieved strong profit growth and margin expansion despite a soft demand environment and slight revenue decline, demonstrating business resilience and quality.
Completed strategic divestments of Talc and Chromium, transforming into a pure-play specialty chemicals business focused on personal care and coatings, and acquired Alchemy Ingredients.
Announced sale of the pharmaceutical business to ABF for ~$40m, further sharpening strategic focus and expected to uplift 2025 group operating margins.
Launched the Elevate Elementis strategy, targeting mid-single-digit revenue growth, >23% operating margins, and >90% three-year operating cash conversion, with innovation sales rising to 16.4%.
Achieved zero lost time accidents and significantly reduced carbon footprint by nearly 80% since 2019, including a 77% reduction in carbon intensity.
Financial highlights
Adjusted operating profit grew 4.6% to $126.7 million, with a 150 basis point margin improvement to 21.2%.
Adjusted EPS increased 14.2% to $0.137, aided by lower net finance costs and share buyback.
Group revenue declined 1.9% year-over-year to $597.5 million, with coatings volumes down but personal care volumes up.
Free cash flow was $41 million, down from $51 million, due to working capital outflow and higher CapEx.
Net debt ended at $185.4 million, with net debt/EBITDA at 1.3x after acquisitions and shareholder returns.
Outlook and guidance
Confident in delivering organic growth through R&D, customer intimacy, best-in-class service, and operational efficiency in 2026.
New mid-term targets: mid-single-digit revenue growth, operating margin above 23%, operating cash conversion above 90%, and ROCE above 30%.
2026 guidance: capex at 4-5% of revenue, net finance costs ~$20m, effective tax rate ~25%.
Board recommended a final dividend of GBP 0.03, full year up 7.5% to GBP 0.043 (31% payout ratio).
Proceeds from pharma business sale expected to be distributed to shareholders upon completion.
Latest events from Elementis
- Adjusted profit up 24%, margin at 17%, and Talc review after $66m impairment.ELM
H1 20242 Feb 2026 - Adjusted operating profit and margins improved year-over-year, with strong cash flow and strategic actions.ELM
Q4 2025 TU21 Jan 2026 - Strong 2024 growth, margin expansion, and cost savings position for 2026 targets.ELM
H2 20242 Dec 2025 - Talc business sold for $121m, enabling $50m buyback and sharper specialty focus.ELM
Investor Update21 Nov 2025 - Adjusted profit and margins up, net debt down, and $50m buyback supports strong outlook.ELM
H1 202516 Nov 2025 - Q3 revenue up 2% year-over-year, guidance maintained, and key leadership transitions announced.ELM
Trading Update29 Oct 2025 - Resilient Q3 performance, steady margins, and full-year guidance reaffirmed.ELM
Trading Update13 Jun 2025 - Profit and margin growth achieved amid weak demand; cost savings and outlook on track.ELM
Trading Update6 Jun 2025